Affinage

MCM6

DNA replication licensing factor MCM6 · UniProt Q14566

Length
821 aa
Mass
92.9 kDa
Annotated
2026-06-10
57 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MCM6 is a core subunit of the heterohexameric MCM2-7 replicative helicase that drives origin licensing and DNA unwinding during the G1/S transition (PMID:10567526, PMID:9286856, PMID:20484375). Within the MCM4-MCM6-MCM7 sub-complex, the ATP-binding activity of MCM6 is critical for helicase function: mutagenesis of its conserved Walker A/B ATPase motifs abolishes unwinding, and its ATPase active site (with MCM2) contributes to the Mcm2/5 'gate' that gates the hexameric ring, while ssDNA binding maps to MCM4 (PMID:10567526, PMID:20484375). MCM6 is loaded onto chromatin at replication origins during G1 phase in an ORC-dependent manner, where it associates with other MCM subunits and exists in both chromatin-bound and soluble forms across the cell cycle (PMID:10490657, PMID:9286856, PMID:9516426, PMID:20398392). Origin licensing is mediated by a direct interaction between Cdt1 and the C-terminal Cdt1-binding domain (CBD) of MCM6, a domain that adopts a winged-helix fold; small molecules that occupy the CBD competitively block the MCM6-CDT1 interaction, arresting cells in G0/G1 (PMID:12192004, PMID:20623209, PMID:39579921, PMID:41203057). Helicase activity is restrained by CDK- and EBV-PK-mediated phosphorylation, and MCM6 additionally couples replication to genome surveillance by binding the checkpoint mediator Mrc1/Claspin to activate the MMS-induced replication checkpoint and by binding the BLM helicase in a cell-cycle-phase-specific manner to limit replication fork speed (PMID:17005684, PMID:19620285, PMID:34370039). MCM6 abundance is controlled transcriptionally by E2F and, in cancer, by YAP-TEAD and c-Myc, and post-translationally by ubiquitination (RNF125, RNF8) and SIRT7-mediated K599 crotonylation that accompanies MCM2-7 disassembly under replication stress (PMID:10327050, PMID:39477811, PMID:38298426, PMID:36185598, PMID:39805445). A de novo missense variant disrupting a zinc-binding cysteine of the MCM6 zinc finger impairs ciliogenesis and proliferation in patient fibroblasts, linking MCM6 dysfunction to human disease (PMID:37198333).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1997 Medium

    Established that human MCM6 is a physical component of a heteromeric MCM complex and that its localization is cell-cycle regulated, peaking at G1/S, defining it as a replication-associated factor.

    Evidence Co-immunoprecipitation with MCM2/MCM7 and subcellular fractionation across synchronized cells

    PMID:9286856

    Open questions at the time
    • Did not resolve the stoichiometry or which subunits contact MCM6 directly
    • No functional readout of the complex
  2. 1999 High

    Defined the enzymatic core of MCM6 by showing its ATP-binding activity is essential for helicase function of the MCM4-6-7 sub-complex, separating helicase from ssDNA-binding activities.

    Evidence Recombinant mouse MCM4/6/7 with Walker A/B motif mutagenesis and in vitro helicase and ssDNA-binding assays

    PMID:10567526

    Open questions at the time
    • MCM4-6-7 sub-complex is not the physiological MCM2-7 ring
    • Did not address how ATP hydrolysis is coupled to translocation
  3. 1999 Medium

    Connected MCM6 expression to cell-cycle entry by showing E2F drives its transcription, explaining serum-responsive induction of licensing capacity.

    Evidence Promoter mutagenesis, luciferase reporters and forced E2F1 expression in REF52 cells

    PMID:10327050

    Open questions at the time
    • Did not establish which endogenous E2F member dominates in vivo
    • No link to protein-level licensing output
  4. 1999 High

    Showed origin loading of MCM6 in vivo by mapping the fission yeast ortholog to specific replication origins in an ORC-dependent, G1/S-restricted manner.

    Evidence Cell fractionation, spread-nuclei immunostaining and ChIP at ars2004/ars3002 in S. pombe

    PMID:10490657

    Open questions at the time
    • Ortholog system; human origin engagement inferred
    • Loading mechanism beyond ORC not resolved here
  5. 2002 High

    Identified the direct licensing contact by mapping a Cdt1-MCM6 interaction through Cdt1's C-terminal region, distinguishing it from the geminin-regulated DNA-binding domain.

    Evidence Yeast two-hybrid, purified-protein binding and domain mapping of mouse Cdt1

    PMID:12192004

    Open questions at the time
    • Did not localize the reciprocal MCM6 binding surface in this study
    • Geminin's effect on loading kinetics not measured
  6. 2006 High

    Defined phosphoregulation of the helicase, showing CDK and EBV-PK phosphorylation (including of MCM6) inactivates the MCM4-6-7 complex.

    Evidence In vitro kinase assays with CDK2/cyclin A and EBV-PK plus MCM4 mutagenesis and helicase readouts

    PMID:17005684

    Open questions at the time
    • MCM6 phosphosites not precisely mapped
    • Physiological relevance in the MCM2-7 ring not tested
  7. 2009 High

    Revealed a checkpoint-sensing role by mapping a direct Mcm6 C-terminus to Mrc1 coiled-coil interaction required specifically for the MMS-induced replication checkpoint.

    Evidence Two-hybrid, reciprocal Co-IP, point mutagenesis and fusion-rescue genetics in budding yeast

    PMID:19620285

    Open questions at the time
    • HU-induced checkpoint is independent of this interaction
    • Human Claspin equivalence not directly tested
  8. 2010 High

    Refined the catalytic architecture by showing the Mcm6/2 ATPase active site contributes to the Mcm2/5 gate that modulates Mcm2-7 helicase activity.

    Evidence Walker B and arginine-finger mutagenesis across individual active sites with in vitro ATPase/helicase assays in S. cerevisiae

    PMID:20484375

    Open questions at the time
    • Gate opening dynamics not directly visualized
    • Coupling to DNA loading versus unwinding not separated
  9. 2010 Medium

    Linked chromatin-bound MCM6 levels to commitment past the restriction point, defining distinct G1 populations with different cycling fates.

    Evidence Flow cytometry with detergent extraction and serum-withdrawal/drug arrest kinetics across cell lines

    PMID:20398392

    Open questions at the time
    • Correlative rather than causal link to restriction-point control
    • Molecular trigger for the high-Mcm6* state unknown
  10. 2010 Medium

    Provided structural identity for the licensing module by showing the MCM6 CBD adopts a winged-helix fold.

    Evidence Triple-resonance NMR chemical-shift assignments of human MCM6 CBD (BMRB 16396)

    PMID:20623209

    Open questions at the time
    • Assignments only; no full structure or Cdt1-bound complex
    • No mutagenesis of the binding interface in this work
  11. 2021 High

    Uncovered a fork-speed control mechanism via phase-specific BLM-Mcm6 interactions, with the S-phase contact restraining replication speed and protecting genome integrity.

    Evidence BLM complex composition, domain-specific binding to N-/C-terminal Mcm6, replication speed and DSB-repair assays with BLM helicase mutants

    PMID:34370039

    Open questions at the time
    • Switch mechanism between N-terminal and CBD sites not resolved
    • How accelerated forks cause DSBs mechanistically unclear
  12. 2023 Medium

    Linked MCM6 to human Mendelian disease by showing a de novo zinc-finger cysteine variant impairs ciliogenesis and proliferation.

    Evidence Trio exome/genome sequencing and patient-derived fibroblast functional assays

    PMID:37198333

    Open questions at the time
    • Helicase-level consequence of the variant not directly measured
    • Mechanistic basis of the ciliary phenotype unresolved
  13. 2024 Medium

    Defined PTM-based regulation of complex stability by identifying SIRT7-mediated K599 crotonylation, coupled to RNF8 ubiquitination, that accompanies MCM2-7 disassembly under replication stress.

    Evidence Site mapping, Kcr western blotting, knockdown replication assays and RNF8 ubiquitination assays

    PMID:39477811

    Open questions at the time
    • Causal order of crotonylation versus ubiquitination not established
    • Direct effect of K599cr on helicase activity not measured
  14. 2024 Medium

    Identified RNF125 as an E3 ligase that ubiquitinates MCM6 and drives proliferation through it in hepatocellular carcinoma.

    Evidence Pull-down, Co-IP, ubiquitination assay and MCM6 rescue co-transfection

    PMID:38298426

    Open questions at the time
    • Whether ubiquitination is degradative or signaling not resolved
    • Lysine target sites not mapped
  15. 2022 High

    Placed MCM6 in oncogenic transcriptional circuitry as a direct YAP-TEAD target that feeds PI3K/Akt signaling and supports the ATR/Chk1 damage response.

    Evidence RNA-seq, ChIP-PCR, luciferase reporters, organoid/xenograft knockdown and pathway western blots in gastric cancer

    PMID:36185598

    Open questions at the time
    • Whether the PI3K/Akt link is direct or replication-dependent unclear
    • Mechanism connecting MCM6 loss to ATR/Chk1 failure not detailed
  16. 2025 Medium

    Established a c-Myc/MCM6 positive feedback loop supporting DNA damage repair and cisplatin resistance.

    Evidence Knockdown/overexpression, ChIP for c-Myc on MCM6 promoter, ubiquitination and DDR assays, xenograft chemosensitivity

    PMID:39805445

    Open questions at the time
    • Direct biochemical basis of MCM6-promoted c-Myc stabilization unclear
    • Single tumor context
  17. 2025 Medium

    Demonstrated druggability of the MCM6 CBD with multiple small molecules that competitively block CDT1 binding and arrest cells, with MCM6/CDT1 overexpression rescuing toxicity.

    Evidence Modified ELISA, DARTS, molecular docking and cell-cycle/apoptosis assays with avermectin B1a and emodepside

    PMID:39579921 PMID:41203057

    Open questions at the time
    • Residue-level binding from docking not all confirmed structurally
    • Selectivity over other winged-helix domains untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the diverse cancer-context signaling roles (ERK/EMT, E2F1, decidualization) mechanistically derive from the core licensing/helicase function of MCM6 remains unresolved.
  • No direct biochemical link between MCM6 helicase activity and ERK/EMT outputs
  • Whether non-replication roles reflect off-complex MCM6 is unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003677 DNA binding 2 GO:0140097 catalytic activity, acting on DNA 2 GO:0140657 ATP-dependent activity 2 GO:0016787 hydrolase activity 1
Localization
GO:0000228 nuclear chromosome 3 GO:0005634 nucleus 1
Pathway
R-HSA-1640170 Cell Cycle 3 R-HSA-69306 DNA Replication 3 R-HSA-73894 DNA Repair 2 R-HSA-8953897 Cellular responses to stimuli 2
Partners
BLMCDT1MCM2MCM4MCM7MRC1RNF125RNF8
Complex memberships
MCM2-7 helicaseMCM4-MCM6-MCM7 sub-complex

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 The ATP binding activity of MCM6 within the MCM4-MCM6-MCM7 complex is critical for DNA helicase activity of the complex; mutagenesis of conserved ATPase motifs in MCM6 abolished helicase activity, while MCM4 contributes to single-stranded DNA binding. The helicase and ssDNA binding activities of the complex can be separated. Expression of mouse MCM4/6/7 in insect cells; Walker A/B ATPase motif mutagenesis; in vitro helicase and ssDNA binding assays Molecular and cellular biology High 10567526
1999 Human MCM5 and MCM6 gene transcription is regulated by E2F transcription factor binding to multiple E2F sites in their promoters; mutation of E2F sites in the MCM6 promoter abolished serum-stimulated promoter activity, and forced E2F1 expression induced endogenous MCM6 expression. Promoter mutagenesis, luciferase reporter assays, exogenous E2F1 expression in REF52 cells Oncogene Medium 10327050
1999 Fission yeast SpMcm6p (encoded by mis5+) associates with chromatin DNA specifically during G1 and S phases, localizes to discrete foci on chromatin at replication origins (ars2004 and ars3002) as shown by chromatin immunoprecipitation, and is loaded onto origins by ORC. Cell fractionation, immunostaining of spread nuclei, chromatin immunoprecipitation assay Molecular and cellular biology High 10490657
1997 Human MCM6 protein (HsMcm6) undergoes cell-cycle-dependent changes in subcellular localization, peaking at G1/S phase; it exists in two forms (detergent-extractable and nucleus-bound) and co-immunoprecipitates with HsMcm2 and HsMcm7 in vivo, forming a heteromeric complex. Immunoprecipitation, subcellular fractionation with NP-40 extraction, cell cycle synchronization and western blotting Genes to cells : devoted to molecular & cellular mechanisms Medium 9286856
1998 Human MCM6 protein associates with chromatin as part of a multiprotein complex containing other MCM proteins, as demonstrated by micrococcal nuclease digestion releasing MCM6-containing complexes from chromatin; a fraction of MCM6 also occurs as a monomer on chromatin. Micrococcal nuclease digestion of chromatin, western blotting, co-fractionation The Journal of biological chemistry Medium 9516426
2002 Mouse Cdt1 directly interacts with MCM6 via the conserved carboxyl-terminal region of Cdt1 (amino acids 407–477); geminin inhibits Cdt1's DNA binding activity (which overlaps with the geminin-binding domain, aa 177–380) but does not directly block the Cdt1–MCM6 interaction domain. Yeast two-hybrid analysis, bacterial expression and purification of mouse Cdt1, domain-mapping experiments, DNA-binding assays The Journal of biological chemistry High 12192004
2006 Phosphorylation of MCM4 at Thr-19 and Thr-110 by CDK2/CDK1 inactivates the MCM4-MCM6-MCM7 helicase complex; EBV protein kinase (EBV-PK) also phosphorylates MCM6 and additional MCM4 sites to further inhibit helicase activity. Introducing N-terminal MCM4 mutations reduced CDK2/cyclin A inhibition but EBV-PK still inhibited both wild-type and mutant complexes, confirming MCM6 phosphorylation contributes. In vitro kinase assays with CDK2/cyclin A and EBV-PK on MCM4-6-7 hexamer; site-directed mutagenesis of MCM4; helicase activity assays Journal of virology High 17005684
2009 Budding yeast Mcm6 directly binds to the checkpoint mediator Mrc1 via the 168-aa C-terminal region of Mcm6 and the conserved coiled-coil region of Mrc1; two amino acid substitutions in Mcm6's C-terminal region abolish this interaction and cause a severe defect in DNA replication checkpoint activation specifically in response to MMS-induced stress (but not HU), and the phenotype is suppressed by fusing Mcm6 directly to Mrc1. Two-hybrid interaction screen, in vivo co-immunoprecipitation, point mutagenesis, checkpoint assays with MMS and HU, genetic fusion rescue experiment Molecular and cellular biology High 19620285
2010 The Mcm6/2 and Mcm5/3 ATPase active sites (defined by Walker B box and arginine finger motifs) contribute to the function of the putative Mcm2/5 'gate' in the Saccharomyces cerevisiae Mcm2-7 hexameric helicase ring; mutational analysis shows these sites modulate overall Mcm2-7 activity differentially. Walker B box and arginine finger mutagenesis at individual Mcm2-7 ATPase active sites; in vitro ATPase and helicase activity assays Nucleic acids research High 20484375
2010 Chromatin-bound MCM6 (Mcm6*) in G1 phase exists in two distinct populations (low and high) separated by the restriction point; cells with high Mcm6* levels reside in late G1 and cycle with committed phases (S, G2, M), as shown by kinetic serum withdrawal and aphidicolin/mimosine/nocodazole experiments. Flow cytometry with Triton X-100 extraction followed by methanol fixation; antibody staining for Mcm6*, PCNA*, DNA content, and mitotic marker; serum starvation/release kinetics BMC cell biology Medium 20398392
2021 BLM helicase directly and physically interacts with the N-terminal domain of Mcm6 in G1 phase and switches to the C-terminal Cdt1-binding domain of Mcm6 in S-phase (a third site mediates binding after DNA damage). Disruption of the BLM–Mcm6 S-phase interaction leads to supra-normal DNA replication speed in unperturbed cells (requiring BLM helicase activity), delayed repair of replication-dependent DSBs, and hypersensitivity to DNA damage and replication stress. Identification of BLM complex composition during S-phase, direct binding assays with distinct Mcm6 domains, cell-based replication speed assays, DNA damage repair assays, BLM helicase mutant analysis Nucleic acids research High 34370039
2010 NMR chemical shift assignments of the Cdt1-binding domain (CBD) of human MCM6 show it adopts a 'winged-helix' fold typical of protein–nucleic acid interaction domains; this domain directly mediates the Cdt1–MCM6 interaction for chromatin loading of the MCM2-7 complex. Triple-resonance NMR spectroscopy; chemical shift assignments deposited (BMRB 16396) Biomolecular NMR assignments Medium 20623209
2024 SIRT7-mediated lysine crotonylation of MCM6 at K599 (MCM6-K599cr) is upregulated in response to DNA replication stress; this crotonylation is associated with disassembly of the MCM2-7 complex and is regulated by RNF8-mediated ubiquitination of MCM6. Western blotting for Kcr marks, MCM6 knockdown proliferation/DNA replication assays, identification of K599 crotonylation site, RNF8 co-expression ubiquitination assays, kaempferol treatment as SIRT7 regulator Cell proliferation Medium 39477811
2024 RNF125 E3 ubiquitin ligase interacts with MCM6 and mediates its ubiquitination; co-transfection experiments show RNF125 promotes HCC cell proliferation mainly through MCM6. Pull-down assay, co-immunoprecipitation, ubiquitination assay, co-transfection with MCM6 rescue Oncology letters Medium 38298426
2024 Avermectin B1a binds to the CDT1-binding domain (CBD) of MCM6 (at residues Glu763, Ile760, Arg771, Glu774), blocking the MCM6–CDT1 interaction and thereby inhibiting DNA replication licensing, causing G0/G1 cell cycle arrest and apoptosis; overexpression of MCM6 or CDT1 reverses these cytotoxic effects. Molecular docking, modified ELISA-based binding assay, cell cycle analysis, viability assays, MCM6/CDT1 overexpression rescue Environmental pollution Medium 39579921
2022 MCM6 is a direct transcriptional target of the YAP-TEAD complex in gastric cancer; the YAP-TEAD complex binds to the MCM6 promoter to induce transcription. MCM6 in turn activates PI3K/Akt/GSK3β signaling. MCM6 deficiency sensitizes cells to chemo/radiotherapy by causing DNA breaks and blocking ATR/Chk1-mediated DNA damage response. RNA sequencing, microarray, chromatin immunoprecipitation PCR (YAP-TEAD binding to MCM6 promoter), luciferase reporter assays, MCM6 knockdown in organoids and xenografts, western blotting for PI3K/Akt/GSK3β and ATR/Chk1 pathway components Theranostics High 36185598
2021 MCM6 knockdown in HCC cells promotes EMT and activates MEK/ERK signaling (decreased pERK, decreased EMT markers upon knockdown); MCM6 expression also promotes MEK/ERK-driven migration and invasion in vivo. Western blotting for ERK pathway and EMT markers, immunofluorescence staining, subcutaneous and orthotopic xenograft models, wound healing, Transwell assays Journal of experimental & clinical cancer research Medium 29357919
2018 MCM6 knockdown in HCC cells causes a delay in S/G2-phase progression accompanied by downregulation of CDK2, CDK4, CyclinA, CyclinB1, CyclinD1, and CyclinE. siRNA knockdown, flow cytometry cell cycle analysis, western blotting for cyclins and CDKs BMC cancer Medium 29463213
2023 MCM6 promotes ICC (intrahepatic cholangiocarcinoma) progression by upregulating E2F1, which mediates EMT; E2F1 knockdown partially blocked the pro-malignant effects of MCM6 overexpression, placing MCM6 upstream of E2F1 in this pathway. GSEA, MCM6 knockdown and overexpression, western blotting and functional assays, E2F1 rescue knockdown experiments, in vivo xenograft Carcinogenesis Medium 37185675
2025 MCM6 promotes cisplatin resistance in bladder cancer by enhancing DNA damage repair (DDR); MCM6 knockdown reduced nuclear c-Myc levels and promoted its ubiquitin-mediated degradation, increasing DNA damage. Conversely, c-Myc (as a transcription factor) binds the MCM6 promoter to drive MCM6 transcription, forming a positive feedback loop. MCM6 knockdown/overexpression, western blotting for DDR markers and c-Myc, ubiquitination assays, chromatin immunoprecipitation for c-Myc binding to MCM6 promoter, in vivo xenograft cisplatin sensitivity International journal of biological macromolecules Medium 39805445
2023 MCM6 interacts with E6AP (UBE3A) ubiquitin ligase (identified by yeast two-hybrid); however, E6AP knockout enhanced ubiquitination of MCM2/4/6, indicating E6AP is not the E3 ubiquitin ligase for these MCM proteins. Ablation of both MCM6 and E6AP synergistically suppressed proliferation and migration of lung adenocarcinoma cells in vitro and in vivo. Yeast two-hybrid assay (MCM6–E6AP interaction), ubiquitination assays upon E6AP KO, proliferation/migration assays, nude mouse xenograft models FEBS open bio Medium 37454373
2025 Emodepside directly binds to the CDT1-binding domain (CBD) of MCM6 at residues Lys754, Ile760, and Lys770, competitively blocking the MCM6–CDT1 interaction, inhibiting DNA replication licensing, causing G0/G1 cell cycle arrest and apoptosis in human corneal stromal cells. Modified ELISA binding assay, drug affinity responsive target stability (DARTS) assay, molecular docking, EdU incorporation assay, cell cycle and apoptosis analysis Toxicology Medium 41203057
2023 De novo MCM6 missense variant p.(Cys158Tyr), affecting a zinc-binding cysteine in the MCM6 zinc finger signature, causes defects in both ciliogenesis and cell proliferation in patient-derived fibroblasts, consistent with an essential role of the zinc-binding domain in MCM-complex dimerization and helicase activity induction. Trio exome/genome sequencing, patient-derived fibroblast functional assays for ciliogenesis and cell proliferation Human genetics Medium 37198333
2024 MCM6 inhibits decidualization of human endometrial stromal cells; MCM6 overexpression promotes G1/S transition and restores proliferation inhibited by E2+P4 treatment via aberrant ERK activation; treatment with ERK agonist Ro 67-7476 restores MCM6 expression, revealing a MCM6/ERK feedback loop that negatively regulates decidualization. In vitro decidualization model with E2+P4, MCM6 overexpression, flow cytometry cell cycle analysis, western blotting for ERK pathway, ERK agonist treatment Reproductive sciences Low 38347378

Source papers

Stage 0 corpus · 57 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1999 Biochemical analysis of the intrinsic Mcm4-Mcm6-mcm7 DNA helicase activity. Molecular and cellular biology 180 10567526
1999 Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene 128 10327050
2002 Mouse geminin inhibits not only Cdt1-MCM6 interactions but also a novel intrinsic Cdt1 DNA binding activity. The Journal of biological chemistry 116 12192004
2018 MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression. BMC cancer 105 29463213
1999 Association of fission yeast Orp1 and Mcm6 proteins with chromosomal replication origins. Molecular and cellular biology 85 10490657
2008 Expression patterns and cell cycle profiles of PCNA, MCM6, cyclin D1, cyclin A2, cyclin B1, and phosphorylated histone H3 in the developing mouse retina. Developmental dynamics : an official publication of the American Association of Anatomists 67 18265020
2018 MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence. Journal of experimental & clinical cancer research : CR 58 29357919
2021 The DNA replication regulator MCM6: An emerging cancer biomarker and target. Clinica chimica acta; international journal of clinical chemistry 55 33609557
2009 The direct binding of Mrc1, a checkpoint mediator, to Mcm6, a replication helicase, is essential for the replication checkpoint against methyl methanesulfonate-induced stress. Molecular and cellular biology 55 19620285
2006 Phosphorylation of MCM4 at sites inactivating DNA helicase activity of the MCM4-MCM6-MCM7 complex during Epstein-Barr virus productive replication. Journal of virology 55 17005684
2011 A single subunit MCM6 from pea promotes salinity stress tolerance without affecting yield. Plant molecular biology 52 21365356
2012 Wolbachia-induced aae-miR-12 miRNA negatively regulates the expression of MCT1 and MCM6 genes in Wolbachia-infected mosquito cell line. PloS one 49 23166816
2010 The Saccharomyces cerevisiae Mcm6/2 and Mcm5/3 ATPase active sites contribute to the function of the putative Mcm2-7 'gate'. Nucleic acids research 47 20484375
2022 MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target. Theranostics 38 36185598
2012 Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome. The American journal of surgical pathology 33 22020044
1997 HsMCM6: a new member of the human MCM/P1 family encodes a protein homologous to fission yeast Mis5. Genes to cells : devoted to molecular & cellular mechanisms 31 9286856
2017 Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma. Virchows Archiv : an international journal of pathology 29 29243125
2006 The fertilization-induced DNA replication factor MCM6 of maize shuttles between cytoplasm and nucleus, and is essential for plant growth and development. Plant physiology 28 16407440
2004 Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors. American journal of clinical pathology 26 15539383
1996 Characterisation of a human homologue of a yeast cell division cycle gene, MCM6, located adjacent to the 5' end of the lactase gene on chromosome 2q21. FEBS letters 26 8977093
2021 MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma. BMC cancer 25 34233647
1998 Human protein MCM6 on HeLa cell chromatin. The Journal of biological chemistry 24 9516426
2021 Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway. Aging 22 33668040
2010 A single subunit MCM6 from pea forms homohexamer and functions as DNA helicase. Plant molecular biology 21 20730596
1996 A novel human Mcm protein: homology to the yeast replication protein Mis5 and chromosomal location. Genomics 19 8921380
2024 In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene. Scientific reports 15 38773180
2020 The impact of MCM6 on hepatocellular carcinoma in a Southern Chinese Zhuang population. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 14 32403044
2023 Benvitimod inhibits MCM6-meditated proliferation of keratinocytes by regulating the JAK/STAT3 pathway. Journal of dermatological science 12 36774328
2021 A novel cell-cycle-regulated interaction of the Bloom syndrome helicase BLM with Mcm6 controls replication-linked processes. Nucleic acids research 12 34370039
2010 Cytometry of chromatin bound Mcm6 and PCNA identifies two states in G1 that are separated functionally by the G1 restriction point. BMC cell biology 12 20398392
1998 cDNA cloning and expression during development of Drosophila melanogaster MCM3, MCM6 and MCM7. Gene 12 9795205
2011 Promoter of a salinity and cold stress-induced MCM6 DNA helicase from pea. Plant signaling & behavior 11 21691155
2022 MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers. Diagnostic pathology 10 35125121
2024 Crotonylation of MCM6 enhances chemotherapeutics sensitivity of breast cancer via inducing DNA replication stress. Cell proliferation 9 39477811
2023 Hypoxia Induces Tumor-Derived Exosome SNHG16 to Mediate Nasopharyngeal Carcinoma Progression through the miR-23b-5p/MCM6 Pathway. Applied biochemistry and biotechnology 9 37119503
2007 Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor. Journal of neuro-oncology 9 17410335
2023 MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition. Carcinogenesis 8 37185675
2022 MCM6 Promotes Hepatocellular Carcinoma Progression via the Notch Pathway: Clinical, Functional, and Genomic Insights. Computational and mathematical methods in medicine 8 35720029
2012 Impact of salinity-tolerant MCM6 transgenic tobacco on soil enzymatic activities and the functional diversity of rhizosphere microbial communities. Research in microbiology 8 22989673
2024 RNF125‑mediated ubiquitination of MCM6 regulates the proliferation of human liver hepatocellular carcinoma cells. Oncology letters 7 38298426
2023 UBE3A and MCM6 synergistically regulate the proliferation and migration of lung adenocarcinoma cells. FEBS open bio 6 37454373
2015 Development of stapled helical peptides to perturb the Cdt1-Mcm6 interaction. Journal of peptide science : an official publication of the European Peptide Society 5 25921752
2023 De novo MCM6 variants in neurodevelopmental disorders: a recognizable phenotype related to zinc binding residues. Human genetics 4 37198333
2014 Are there differences between patients with and without the homozygous--13910CC genetic variant in the MCM-6 gene upstream from the lactase gene?--A non-randomised, two armed intervention study without control group. Clinical laboratory 4 25651706
2024 Pesticide avermectin B1a exerts cytotoxicity by blocking the interaction between mini-chromosome maintenance 6 protein (MCM6) and chromatin licensing and DNA replication factor 1 (CDT1). Environmental pollution (Barking, Essex : 1987) 3 39579921
2025 The MCM6-c-Myc positive feedback loop mediates bladder cancer progression and cisplatin resistance. International journal of biological macromolecules 2 39805445
2025 Roles of MARCKSL1, MCM6, RFC4, and PLAU genes in esophageal cancer and their association with radiotherapy response. Scientific reports 2 40603489
2023 Genome-wide binding sites of Plasmodium falciparum mini chromosome maintenance protein MCM6 show new insights into parasite DNA replication. Biochimica et biophysica acta. Molecular cell research 2 37482133
2011 Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin. Plant signaling & behavior 2 21336027
2026 Frequency and Diagnostic Utility of the -13910C>T MCM6 Gene Polymorphism for Lactose Intolerance in a Brazilian Northeast Population. In vivo (Athens, Greece) 0 41482367
2026 Circular Circ_0001387 Promotes Hepatocellular Carcinoma Progression via miR-4324/MCM6 Axis and Cell Cycle Pathway Activation. Current medicinal chemistry 0 42152669
2025 Antiparasitic agent emodepside exerts cytotoxicity in human corneal stromal cells by blocking the interaction between mini-chromosome maintenance 6 protein (MCM6) and chromatin licensing and DNA replication factor 1 (CDT1). Toxicology 0 41203057
2025 Targeting MCM6 Enhances Melphalan Chemosensitivity in Retinoblastoma by Modulating DNA Damage Response. Investigative ophthalmology & visual science 0 41334961
2025 TCF19 promotes gastric cancer progression through MCM6. BMC gastroenterology 0 41398215
2024 MCM6 Inhibits Decidualization via Cross-Talking with ERK Pathway in Human Endometrial Stromal Cells. Reproductive sciences (Thousand Oaks, Calif.) 0 38347378
2023 Retracted: MCM6 Promotes Hepatocellular Carcinoma Progression via the Notch Pathway: Clinical, Functional, and Genomic Insights. Computational and mathematical methods in medicine 0 37475947
2010 1H, 15N and 13C chemical shift assignments of the Cdt1 binding domain of human Mcm6. Biomolecular NMR assignments 0 20623209

Missed literature

Know a paper Affinage missed for MCM6? Flag it for the maintainers and the community.

No submissions yet.